OTC · Biotechnology

Clinuvel Pharmaceuticals Limited (CLVLF) Stock

$6.37 +0.00% OTC: CLVLF Healthcare

Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the United States, Switzerland, and various international markets.

Valuation

MetricValue
Price$6.37
Market Cap$321.12M
P/E Ratio13.94
P/B Ratio1.82
P/S Ratio4.74
EPS (TTM)$0.46
52-Week High$8.60
52-Week Low$6.10
Dividend Yield0.47%

Financials & Margins

MetricValue
ROE13.29%
ROA12.07%
ROCE15.06%
Gross Margin63.71%
Operating Margin39.39%
Net Margin33.79%
Debt/Equity0.00
Current Ratio14.64

Annual Financials (USD)

Metric20212022202320242025
Revenue$48.0M$66.0M$78.0M$88.0M$95.0M
Operating Profit$29.0M$36.0M$45.0M$48.0M$46.0M
Net Profit$25.0M$21.0M$31.0M$36.0M$36.0M
EPS$0.48$0.40$0.59$0.70$0.72
Op Margin60.9%54.9%57.3%54.4%48.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$109.0M$144.0M$194.0M$231.0M$272.0M
Total Liabilities$10.0M$18.0M$29.0M$28.0M$31.0M
Cash$83.0M$122.0M$157.0M$184.0M$224.0M
Borrowings$1.0M$1.0M$1.0M$1.0M$1.0M

Latest News

CLINUVEL implements strategic reorganisation to refocus on U.S. markets GlobeNewswire · Jul 23, 2026 CLINUVEL’s ADS to commence trading on Nasdaq GlobeNewswire · Jul 20, 2026 SCENESSE® approved for EPP in Canada GlobeNewswire · Jul 13, 2026 3 ASX Growth Stocks With High Insider Ownership Growing Earnings At 24% Simply Wall St. · Jun 11, 2026 High Growth Tech Stocks in Australia for May 2026 Simply Wall St. · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$19.0M$40.0M$37.0M$37.0M$41.0M
Investing Cash Flow$-2.0M$-1.0M$-2.0M$-35.0M$-48.0M
Financing Cash Flow$0$0$0$-5.0M$-1.0M
Net Cash Flow$16.0M$39.0M$35.0M$3.0M$-7.0M
Free Cash Flow$18.0M$39.0M$36.0M$31.0M$41.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.89
EV / EBITDA10.11
FCF Yield8.78%
Quick Ratio14.17
Interest Coverage11.50
Return 1Y-20.38%
Return 3Y-47.29%
Return 5Y—

Ownership

Insiders Held16.59%
Institutions Held9.40%
Institutions Float Held11.27%
Institutional HolderSharesReport Date
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund589,6192026-04-30
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund385,0682026-03-31
DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series188,2752026-04-30
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap 160,9682026-04-30
SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF87,8402026-05-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CMVLFCellectis S.A. $3.47 +12.66% -4.24 $251.93M 0.00%
CYDYCytoDyn Inc. $0.19 +0.00% -5.94 $260.25M 0.00%
EAPIFEuroapi S.A. $1.51 +0.00% -0.29 $144.31M 0.00%
FGHQFFrontage Holdings Corporation $0.15 +11.11% 44.83 $304.16M 0.00%
HLOSFHealios K.K. $1.80 +0.00% -9.76 $243.00M 0.00%

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the United States, Switzerland, and various international markets. The company's flagship product is SCENESSE, a systemic photoprotective medication. This drug is specifically designed to prevent light-induced damage in adult individuals diagnosed with erythropoietic protoporphyria (EPP). Beyond its established product, Clinuvel's development pipeline encompasses several other promising compounds. These include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which is recognized for its ability to provoke heightened and sustained cellular activity; and PRÉNUMBRA, an injectable liquid formulation of afamelanotide. Furthermore, Clinuvel has forged a strategic partnership with HK Winhealth Pharma Group Co. Limited. This collaboration aims to provide SCENESSE to EPP patients in the People's Republic of China via a dedicated named patient program.

Clinuvel Pharmaceuticals Limited is headquartered in AU.

Clinuvel Pharmaceuticals Limited (CLVLF) stock trades at $6.37 with a market capitalization of $321.12M. The stock is valued at a price-to-earnings (P/E) ratio of 13.94, price-to-book of 1.82, price-to-sales of 4.74. Over the past 52 weeks the stock has ranged between $6.10 and $8.60, and currently trades 25.9% below its 52-week high. It pays a dividend yielding 0.47%.

On profitability, Clinuvel Pharmaceuticals Limited generates a return on equity (ROE) of 13.29%, above the typical market average, return on capital employed of 15.06%, an operating margin of 39.39%, a net profit margin of 33.79%.

Official website: www.clinuvel.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides